The current state of the global economy as redefined by the COVID-19 epidemic has forced many industries fierce competition over users’ trust, and, of course, capital. Arguably the sector where this is most obvious and logical to happen is the pharmaceutical sphere.
Since the beginning of the pandemic, there have been countless efforts and billion of dollars spent on a vaccine and on attempts at one. The public’s attention shifted, as was expected, while investors saw an opportunity.
The race for a vaccine increased the value for many biotech, bio-pharmaceutical, and pharmaceutical companies.
FBS is one of the first brokers that has introduced pharma stock CFDs, allowing its clients to speculate on future developments, while also capitalising on the companies’ efforts.
The following pharma companies are available to trade with:
- Inovio Pharmaceuticals (INO), a biotech firm, managed a 400% jump in stock prices.
- Moderna (Moderna, Inc.), the Cambridge based biotechnology firm, saw a 100% increase.
- Sanofi (SNY) is a French multinational pharmaceutical firm.
- BioNTech (BNTX), the German biotechnological solutions company, rose its stocks with 100%.
- Emergent (EBS), the multinational speciality biopharmaceutical American company that specialises in vaccines.
- Novavax (NVAX) is a vaccines developing company, that recently received a $89 million donation from the Gates family foundation.
- Gilead (GILD), another American company, focusing on antiviral drugs.
While all these firms exploded on the stock market, it is expected that whoever produces a reliable vaccine will see their stocks increase exponentially, an event for the history books.